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In Vitro and In Vivo Activities of Dicationic Diguanidino Compounds
against Echinococcus multilocularis Metacestodes
Tatiana Küster,a Nadja Kriegel,a David W. Boykin,b Chad E. Stephens,c Andrew Hemphilla
Institute of Parasitology, Vetsuisse Faculty, University of Berne, Berne, Switzerlanda; Department of Chemistry, Georgia State University, Atlanta, Georgia, USAb;
Department of Chemistry and Physics, Georgia Regents University, Augusta, Georgia, USAc
Alveolar echinococcosis (AE) is a disease predominantly affecting the liver, with metacestodes (larvae) of the tapeworm Echino-
coccus multilocularis proliferating and exhibiting tumor-like infiltrative growth. For many years, chemotherapeutical treatment
against alveolar echinococcosis has relied on the benzimidazoles albendazole andmebendazole, which require long treatment
durations and exhibit parasitostatic rather than parasiticidal efficacy. Although benzimidazoles have been and still are beneficial
for the patients, there is clearly a demand for alternative andmore efficient treatment options. Aromatic dications, more pre-
cisely a small panel of di-N-aryl-diguanidino compounds, were screened for efficacy against E. multilocularismetacestodes in
vitro. Only those with a thiophene core group were active against metacestodes, while furans were not. The most active com-
pound, DB1127, was further investigated in terms of in vivo efficacy in mice experimentally infected with E. multilocularismeta-
cestodes. This diguanidino compound was effective against AE when administered intraperitoneally but not when applied orally.
Thus, thiophene-diguanidino derivatives with improved bioavailability when administered orally could lead to treatment op-
tions against AE.
The disease alveolar echinococcosis (AE) is caused by infectionwith the metacestode (larval) stage of the parasitic tapeworm
Echinococcus multilocularis. The adult tapeworm lives within
the intestine of its definitive hosts, mainly foxes (Vulpes vul-
pes), as well as cats and dogs. Several genera of rodents are
intermediate hosts, where asexual proliferation of the larval
stage takes place (1).
AE is a zoonotic disease, and it occursmainly in central Europe
(France, Germany, Switzerland, and Western Austria), North
America, and east Asia, with high fatality in humans if untreated.
However, in the past 10 to 20 years, the occurrence of E. multi-
locularis and AE has increased in northern and eastern Europe (2,
3), South Korea (4), the United States (5), Iran (6), mainland
Japan (7), China (8), Kyrgyzstan (9), and Switzerland (10). It is
very likely that the urbanization of foxes in many central Euro-
pean cities is responsible for the emergence of AE in regions where
the disease was not noticed before (11).
The current strategy for treating human AE consists of surgical
measures complemented by chemotherapy using benzimidazole
compounds (mebendazole or albendazole). These compounds in-
hibit parasite proliferation, making them parasitostatic, but they
do not cure the disease,meaning patients have to undergo chemo-
therapy for extended periods of time, often lifelong. Although
benzimidazoles clearly have beneficial effects for patients in terms
of life quality and survival, the current treatment results in high
costs and elevated risk of adverse effects (12–17). A number of
compounds have been investigated in the past as treatment alter-
natives for AE, using in vitro-cultured parasites and/or in vivo
rodent models. These include other benzimidazole derivatives,
broad-spectrum anti-infective agents, and anticancer drugs (re-
viewed in references 18–20). However, none of the compounds
investigated has been translated into clinical application, either
due to low efficacy, high toxicity, or simply because the pharma-
ceutical industry has not been prepared to invest in a disease with-
out a meaningful market return (21).
Although introduced in 1942, pentamidine is still an important
broad-spectrum antimicrobial compound, with activities against
trypanosomiasis, leishmaniasis, and malaria, as well as pneumo-
cystis pneumonia caused by Pneumocystis jirovecii and Candida
albicans infections (22). Novel diamidines and arylimidamide an-
alogues have been proven effective against visceral leishmaniasis
as well as Trypanosoma cruzi and Neospora caninum infections in
animal models (23–25). The exact mode of action of pentamidine
derivatives, such as diamidines and arylimidamides, has not been
elucidated so far. These dicationic molecules bind to the minor
groove of mitochondrial and nuclear DNA at AT-rich sites and
then inhibit one ormore of theDNA-dependent enzymes (such as
topoisomerases or nucleases) or directly impede the transcription
process.
Themore recent achievements in the in vitro culture of E. mul-
tilocularismetacestodes led to the development and validation of a
drug screening assaywhich is based on the detection of the enzyme
phosphoglucose isomerase (PGI) of E.multilocularis. PGI is abun-
dant in metacestode vesicle fluid and released into the metaces-
tode culture supernatant by dying parasites, while intact, viable
metacestodes do not release this enzyme (26). Recently, we dem-
onstrated that DB1127, a dicationic thiophene derivative (di-N-
aryl-diguanidino compound), triggered the release of high levels
of PGI activity from metacestodes in a dose-dependent manner,
was substantially active at concentrations as low as 1 M, and
induced structural damage upon E. multilocularis metacestodes
(21).
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In this study, we investigated the anti-echinococcal activities of
a small panel of diguanidino compounds, which are structurally
related to DB1127. These included derivatives with a furan core
structure and others with a sulfur substitution in the furan ring
(thiophene). DB1127 was also administered to experimentally in-
fected mice, and the administration route of the drug was proven
to be crucial for its effectiveness.
MATERIALS AND METHODS
In vitro culture of E. multilocularis metacestodes. If not stated other-
wise, all culture media and reagents were purchased from Gibco-BRL
(Zürich, Switzerland), and biochemical reagents were from Sigma (St.
Louis, MO). The culture of E. multilocularis (isolate H95) was carried out
as previously described (27, 28). In short, metacestodes dissected from
experimentally infected BALB/cmice were pressed through an autoclaved
tea sieve. The metacestodes were incubated in antibiotic solutions: 20
g/ml levofloxacin (Aventis, Meyrin, Switzerland) and 20 g/ml cipro-
floxacin (Bayer, Zürich, Switzerland) in phosphate-buffered saline (PBS)
overnight. The sedimented material was washed several times with 1
PBS, and 1 ml was added to a cell culture flask containing 5  106 rat
hepatoma (CRL-1600; ATCC) cells/50 ml cultivation medium (Dulbec-
co’s modified Eagle medium [DMEM], 10% fetal calf serum [FCS], 100
U/ml penicillin G, 100 g/ml streptomycin sulfate). These cocultures
were incubated at 37°C and 5% CO2, with medium changes once a week.
Splitting of cultures was carried out when exceeding 15 ml total metaces-
tode volume. Metacestodes were used for experimental procedures when
they reached diameters of4 mm.
Compounds. The diguanidino compounds investigated in this study
were synthesized by David W. Boykin and Chad. E. Stephens. Nitazox-
anide was synthesized and kindly provided by Christian Leumann (De-
partment of Chemistry, University of Berne), and albendazole was pur-
chased from Sigma (St. Louis, MO).
In vitro drug treatment of Echinococcus multilocularis metaces-
todes. E. multilocularismetacestodes were collected after 1 to 2months of
culture. The screening for effective compounds against the parasite was
performed as described by Stadelmann et al. (26). In short, after extensive
washing with PBS and selection of intact vesicles, they were distributed in
24-well plates. Treatments were carried out in medium without phenol
red (DMEM, 100 U/ml penicillin G, 100 g/ml streptomycin sulfate, 2
mM L-glutamine). The drugs were prepared as stocks of 10 mM in dime-
thylsulfoxide (DMSO) and added to thewells at a final concentration of 20
M (0.2%DMSO) for initial screening or less for studies on dose-depen-
dent effects. After 5 days of incubation at 37°C and 5% CO2, the medium
within the wells was collected and stored at20°C. In parallel, specimens
were viewed by light microscopy to assess potential drug-induced mor-
phological damage.
Assessment of toxicity of compounds for E. multilocularismetaces-
todes. The damage induced upon vesicles incubated with selected drugs
under axenic conditions was assessed indirectly by measuring the release
of PGI into themedium supernatant after 5 days of in vitro treatment (26,
29). The assaywas performed in 96-wellmicrotiter plates (Sarstedt) under
axenic conditions, i.e., in the absence of hepatoma cells. Per well, 95 l of
assay buffer (100 mM Tris-HCl [pH 7.6], 0.5 mM nicotinamide adenine
dinucleotide [NAD; Fluka], 2 mM EDTA [Merck], and 1 U glucose-6-
phosphate dehydrogenase) was mixed with 20 l of each supernatant
aliquot (described above). Measurements were performed in triplicates.
The reaction was started by addition of fructose-6-phosphate (Fluka) to 1
mM. NAD reduction to reduced nicotinamide adenine dinucleotide
(NADH)wasmeasured by reading theA340 everyminute from0 to 30min
with a 96-well plate reader (2300 EnSpire multilabel reader; Perkin-
Elmer, Turku, Finland). Enzyme blanks (no substrate) and substrate
blanks (no enzyme) were also included. Absorbance values of the enzyme
blanks were subtracted from the enzyme reaction values afterwards. The
PGI activity of the untreated group was subtracted from the activity of the
treated groups, as it represents the activity baseline. PGI activity was cal-
culated from the corresponding linear regression parameters (A340/t)
and is presented as a percentage relative to the values obtained by treat-
ment of vesicles with 1% Triton X-100. Linear regression analysis was
performed using Excel (2007).
Assessment of toxicity of compounds for HFF, Vero cells, and RH
cells. Human foreskin fibroblasts (HFF) and rat hepatoma (RH) cells
were seeded in a 96-well microtiter plate (Greiner Bio-One) at a cell den-
sity of 10,000 cells/well. They were cultured at 37°C and 5% CO2 in
DMEMwithout phenol red and supplementedwith 1% L-glutamine, 10%
FCS, 50 U/ml penicillin G, and 50 g/ml streptomycin for 48 h, at which
time the monolayer became confluent. Monkey kidney epithelial (Vero)
cells were cultured similarly, but the initial density of cells per well was
5,000. The compounds DB869, DB871, and DB1127, dissolved in DMSO,
were added to provide final concentrations of 0.5, 1, 5, 10, and 20M. As
a negative control, the cells were treated with medium, and the same
amount of DMSO (final concentration, 0.2%) was present in the treated
groups. As a positive control, the cells were treated with 1%Triton X-100.
After incubation at 37°C and 5% CO2 for 3 days, the cell vitality was
assessed by alamarBlue assay. In short, 1 l of a 200 solution (2 g/liter)
of resazurin was added to each well to a final concentration of 1. Fluo-
rescence at 595 nm was measured in a multilabel plate reader (2300
EnSpire multilabel reader; Perkin-Elmer, Turku, Finland) at 0 and 4 h
after the addition of resazurin to the cells. The values obtained at 0 h were
subtracted from the ones obtained at 4 h.
The percent survival was calculated by standardizing the values to
those of the untreated group (100%). A positive control was not included
in the calculations. For each incubation condition, sextuplets were mea-
sured. Linear regression analysis was performed using Microsoft Excel
(2007).
In vivo studies on the efficacy of DB1127 in experimentally infected
BALB/c mice. The in vivo effects of DB1127 were investigated and com-
pared to those of standard oral albendazole treatments. Two experiments
were performed, one assessing the intraperitoneal (21) and one the oral
(30) delivery route. DB1127 was prepared as a stock solution in DMSO
and diluted 1,000 times with 1% carboxymethyl cellulose (CMC) in saline
solution. The intraperitoneal dosewas of 10mg/kg of bodyweight and 1%
DMSO (final concentration). For oral drug delivery, the drug was directly
emulsified in a 1:1mixture of honey–1%CMC(M-Budget honey;Migros,
Zürich, Switzerland) to 50mg/kg. Albendazole was also emulsified in a 1:1
mixture of honey–1%CMC to 200mg/kg. The animals received the drugs
in a final volume of 100 l.
For experiment 1 (assessment of intraperitoneal injection ofDB1127),
24 female BALB/c mice (age, 9 weeks; average body weight, 25 g) were
housed in a temperature-controlled light cycle room with food and water
ad libitum. Experiments were carried out according to the Swiss Animal
Welfare regulations. All mice were infected intraperitoneally with 100 l
of metacestode vesicle suspension (29) and were randomly allocated into
3 groups of 8 animals each. At 6 weeks postinfection, mice were given the
following daily treatments: group 1 (untreated control group) received
100 l of the honey-CMC mixture orally; group 2 (albendazole control
group) received albendazole (200 mg/kg) in 100 l diluted honey orally;
and group 3 received DB1127 (2 mg/kg in 100l PBS-CMC) intraperito-
neally. The treatments were performed daily for groups 1 and 2 and three
times weekly for group 3, for an overall period of 4 weeks.
For experiment 2 (oral administration of DB1127), 32 female BALB/c
mice (age, 9 weeks; average body weight, 25 g) were infected with E.
multilocularis metacestodes as described above and were divided into 4
groups of 8 animals each. Group 1 (untreated control) received 100 l
CMC-honey only; group 2 (albendazole control group) received albenda-
zole (200 mg/kg) in 100 l CMC-honey; group 3 received DB1127 (50
mg/kg) in 100 l CMC-honey; group 4 received DB1127 (50 mg/kg) in
combination with albendazole (200 mg/kg) in 100 l CMC-honey. Al-
bendazole was administered daily, while DB1127 was provided three
times a week for a period of 6 weeks.
At the end of the studies, the animals were euthanized. After necropsy,
Küster et al.
3830 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 August 6, 2014 by UNIVERSITAET BERN
http://aac.asm
.org/
D
ow
nloaded from
 
the total parasite tissue was collected and the parasite weight determined
and presented as box plots. The data were submitted to a two-tailed dis-
tributed Student t test, with two-sample equal variance determinations
performed using the untreated group and each of the treatment groups
belonging to each experiment.
RESULTS AND DISCUSSION
Effects of diguanidino compounds against E. multilocularis
metacestodes in vitro. The structures of the limited panel of
diguanidino derivatives investigated in this study are depicted in
Table 1. Initial PGI assays were carried out by exposing metaces-
todes to 20 M each compound over a period of 5 days (Fig. 1).
Significantly elevated PGI activity was recorded inmedium super-
natants of metacestodes cultured in the presence of DB1127,
DB869, and DB871 (Fig. 1). The term “% metacestode death” in
Fig. 1 relates to the enzymatic activity in drug-treated parasites
relative to PGI activity obtained from vesicles killed and perme-
abilized by the addition of Triton X-100 (designated 100%). The
morphological alterations due to drug treatment, such as loss of
turgor and vesicle collapse, were also visualized by light micros-
copy (Fig. 1B).Only those compoundswith a thiophene backbone
structure were active against metacestodes, while compounds
with a furan ring were not; thus, the presence of a thiophene ring
is important for antimetacestode activity. This becomes particu-
larly evident when comparing the structures of DB869 and
TABLE 1 Dicationic derivative codes, their IC50 (M) values, and structures
Code IC50
a (M) Structure
DB856 ND
DB857 ND
DB859 ND
DB869 12.3
DB871 11.3
DB872 ND
DB944 ND
DB1127 6.1
a ND, not determined.
FIG 1 Assessment of effects of diguanidino compounds against E. multilocu-
laris metacestodes. (A) In vitro release of E. multilocularis PGI activity upon
treatment ofmetacestodes for 5 days with 20Meach compound. PGI activity
levels are depicted relative to total vesicle damage induced by exposure to 1%
Triton X-100. Error bars indicate standard deviations. (B) Visualization of the
morphology of metacestodes after exposure to 1% Triton X-100, DB1127
(high activity), and DB856 (low activity).
Dicationic Drugs against Alveolar Echinococcosis
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DB859, which are identical, with the exception that the thiophene
ring in the former is replaced by a furan ring in the latter (Fig. 1A).
The dose dependency of DB1127-, DB869-, and DB871-medi-
ated effects was assessed at different concentrations. The broad-
spectrum drug nitazoxanide, previously shown to exhibit pro-
found antimetacestode activity in vitro (26, 31), was used as a
positive control. PGI enzyme activity values of 50% (Fig. 2, 50%
metacestode death) were achieved at a nitazoxanide concentra-
tion of 1.4 M. For DB1127, 6.1 M was required in order to
achieve similar PGI activity release. For DB869 and DB871, 12.3
and 11.2 M, respectively, were needed to induce 50% metaces-
tode death (Table 1). Thus, methyl groups on the terminal ben-
zene rings of these aromatic dications appear to be irrelevant in
terms of anti-Echinococcus activity, since methyl groups are pres-
ent in both DB1127 and DB871 but not in DB869 (Table 1). In
contrast, DB1127 is the only compound with a thiophene group
flanked by two methylated benzene rings, and it is possible that
these methyl groups are important for the increased activity of
DB1127 compared to those of the DB869 and DB871. While the
three compounds exhibit a highly similar molecular structure, the
addition of the methyl group on the internal benzene rings could
provide DB1127 with an increased membrane permeability,
which, in turn, could increase the chances of the drug passing
through several layers of membrane, including the plasma mem-
brane and the membrane of a potential target organelle. This hy-
pothesis is consistent with their CLogP values, which are the fol-
lowing: DB869, 5.72; DB871, 6.72; and DB1127, 7.12. Which
targets are actually affected by DB1127 is not clear. Current evi-
dence suggests that aromatic dicationic compounds bind to AT-
rich sites in the DNA minor groove; thus, they inhibit transcrip-
tion or the interaction with DNA-binding enzymes, such as
topoisomerases or nucleases (32). This indicates that these com-
pounds influence gene expression; thus, many diverse cellular
functions could be affected. Clearly, more analogues need to be
investigated to draw definitive conclusions, and other important
structural requirements may be relevant for antimetacestode ac-
tivity.
Cytotoxicity in HFF, Vero cells, and RH. Dicationic com-
pounds, such as pentamidine and its derivatives, often exhibit a
certain degree of toxicity. Cardiotoxicity, nephrotoxicity, and
pancreatic complications have been reported (33). The cytotoxic-
ity of DB1127, DB869, and DB871 was comparatively assessed in
mammalian cells of human,monkey, and rat origin by alamarBlue
assay. In this assay, viable cells reduce resazurin to resorufin, a
fluorescent substance, which can be quantified at 595 nm, and this
is used as a measure of viability. The term “survival in %” in Fig. 3
relates to the fluorescence measured at 595 nm in relation to the
fluorescence measured from untreated control cultures (desig-
nated 100%). Table 2 shows the observed 50% inhibitory concen-
FIG 2 Dose responses upon treatments of E. multilocularismetacestodes with
thiophene diguanidino compounds. PGI activity inmedium supernatants was
measured after exposure to DB869, DB871, DB1127, and the reference drug
nitazoxanide (NTZ). E. multilocularis metacestodes were incubated in the
presence of the selected compounds (0.5 to 20M) for a period of 5 days. One
hundred percent metacestode death refers to PGI activity in medium super-
natant after treatment with 1% Triton X-100. Error bars indicate standard
deviations.
FIG 3 Cytotoxicity assays. Cytotoxicity of DB869, DB871, and DB1127 was
measured in rat hepatoma cells (A), human foreskin fibroblasts (B), and Vero
cells (C). The cells were grown to confluence and incubated with different
concentrations of the drugs (0.5 to 20M) for 72 h. Assessments weremade by
alamarBlue assay. Values are presented as percentages relative to the values for
controls without the compound. Error bars indicate standard deviations.
TABLE 2 IC50s (M) of compounds DB679, DB681, and DB1127 in
HFF, RH, and Vero cells
Code HFF RH Vero
DB869 7.9 5.5 20
DB871 3.3 5.5 20
DB1127 3.2 3.6 16.5
Küster et al.
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tration (IC50s) for the compounds in different mammalian cells.
Figure 3A shows that all three compounds exhibit considerable
toxicity in RH cell cultures. This is not surprising, since other
studies have demonstrated toxic effects of diamidines in tumor
cells, implying that toxicity was mediated by the nuclear or mito-
chondrial DNA-binding properties and topoisomerase inhibition
(34–36). HFF, representing normal nontransformed cells, were
more sensitive toDB1127 andDB871 than toDB869 (Fig. 3B), but
overall they were more resistant than RH cells. Curiously, all
compounds seemed to display an even more reduced toxicity to
Vero cells, a noncarcinogenic monkey kidney epithelial cell line
(Fig. 3C), than to HFF.
A common feature in all cytotoxicity assays concerns the in-
crease in so-called survival in percent values that are observed
when compounds are applied at low concentrations (Fig. 3A toC).
This is most likely due to the nature of the viability assay, since the
conversion of resazurin to resorufin is actually an indicator of
metabolic activity and is dependent on the presence of NADH. At
sublethal drug concentrations, whichmediate effects on the cellu-
lar metabolism that do not yet compromise the overall viability of
the cells, metabolic activity is likely to be increased, as these cells
seek to compensate for the impairment mediated by the drugs by
increased energy consumption. This idea is supported by light
microscopic inspection of cultures during drug treatments, which
did not reveal any obvious alterations (data not shown). An alter-
native possibility is that in low concentrations these compounds
induce cell proliferation, but no evidence for this has been gener-
ated so far. In conclusion, DB1127, exhibiting the most pro-
nounced in vitro effects against E. multilocularismetacestodes, ap-
peared to be more cytotoxic than DB869 and DB871 in HFF and
Vero cells, while all three compounds were similarly toxic for RH.
In vivo studies employingDB1127 treatment inE.multilocu-
laris-infected mice. The in vivo efficacy of DB1127 was investi-
gated inmice by employing twomodes of drug administration. In
experiment 1, DB1127 was administered by intraperitoneal injec-
tion at a dose of 2 mg/kg three times a week, and the effect of this
treatment was compared to that of the standard albendazole treat-
ment (200 mg/kg applied orally on a daily basis) (37, 38) over a
treatment duration of 4 weeks. In a pilot experiment, two unin-
fected mice were treated with DB1127 at 2 mg/kg for 2 weeks
without exhibiting any overt adverse side effects. Themorphology
of the intraperitoneal cavity remained unaffected despite the fre-
quent injections of the drug (data not shown). Thus, 2 mg/kg was
chosen as the treatment dose. As indicated in Fig. 4A, the standard
oral albendazole treatment resulted in a significant reduction in
the parasite burden by 84%, and DB1127 treatment reduced the
parasite weight significantly by 70% compared to levels for the
untreated control. No distress or other behavioral changes were
observed in the animals during the treatment.
In experiment 2, DB1127 was applied by the oral route, as was
done for albendazole. In a pilot experiment, two uninfected mice
per group were treated with DB1127 at 10, 20, and 50 mg/kg,
respectively, for 2 weeks without exhibiting any adverse side ef-
fects. Thus, a treatment dosage of 50 mg/kg was chosen. After a
treatment period of 6 weeks, albendazole chemotherapy resulted
in a significant reduction in parasite burden (Fig. 4B). However,
no reduction in parasite weight was recorded in DB1127-treated
mice, and no improvement of treatment efficacy was found in
mice receiving albendazole-DB1127 combination treatment. In
fact, the combined application of DB1127 with albendazole com-
promised the treatment efficacy of the benzimidazole. This indi-
cates that drug interactions occur, the nature of which are un-
known at present and need to be investigated further. For
instance, the inclusion of DB1127 could affect the absorption of
albendazole. Dicationic compounds, when applied orally, are
known to be poorly absorbed. The poor bioavailability is attribut-
able, in large part, to the high pKa of the amidine functional group;
thus, at physiological pH, these drugs are dications. If DB1127
interacts with albendazole when combined and applied orally, this
could have an impact on adsorption of the latter. Reuter et al. (39)
demonstrated that in vitro treatment of E. multilocularismetaces-
todes with either albendazole or amphotericin B had a profound
destructive impact on the parasites, and sequential treatments
with the two compounds killed metacestodes. However, simulta-
neous application of the two compounds had an inhibitory effect
on vesicle destruction. Antagonistic effects have been commonly
observed in experimental treatments of other helminth infections.
For instance, a recent study on the activity of albendazole in com-
bination with oxantel pamoate against Trichuris muris in mice
showed that while oxantel pamoate treatment alone was highly
active, the combination with albendazole revealed antagonistic
effects. On the other hand, highly synergistic effects were observed
FIG4 Effects of DB1127 treatment in experimentally infectedmice. The treat-
ment was initiated at 6 weeks after intraperitoneal infection with E. multilocu-
larismetacestodes. Each treatment group comprised 8 animals. (A) Intraper-
itoneal DB1127 treatment was done by injection of 2mg/kg in 100l 1%CMC
in PBS three times/week for a period of 4 weeks, while albendazole (ABZ)
emulsified in honey-CMC was applied orally at 200 mg/kg daily. Note the
significant reduction in parasite weight in both albendazole- and DB1127-
treated mice. (B) Oral DB1127 treatments were administered at 50 mg/kg in
honey-CMC three times a week, and albendazole was given as described for
panel A.DB1127 treatment alonewas ineffective, and combiningDB1127with
albendazole abrogated the beneficial effects of albendazole.
Dicationic Drugs against Alveolar Echinococcosis
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when oxantel pamoate was administered in combination with an-
other benzimidazole, mebendazole (40).
Interestingly, the treatment efficiency of albendazole was vari-
able between the two experiments, as seen by the differences in the
reduction in parasite weights compared to those of the controls
(84% in experiment 1 and 36% in experiment 2). However, the
parasite weights in the controls recovered at the end of the exper-
iment differed substantially in the two experiments, such as a me-
dian weight of 1.2 g in the experiment 1 control group and slightly
below 0.6 g in the control group of experiment 2. First, this reflects
the inherent variation in the experimental system for AE, such as
batch-to-batch variations of parasite material used for infection
experiments, and points out the need for more standardization of
cultured material in order to obtain parasites with highly similar
infectivity. Second, these results indicate that chemotherapy has a
lower impact in hosts infected with a lower parasite load for rea-
sons that are currently unknown. Third, the duration of treatment
(4weeks in experiment 1 and 6weeks in experiment 2)might have
an influence. It remains to be shown whether Echinococcusmeta-
cestodes have acquired the ability to adapt to drug pressure by,
e.g., upregulation of intrinsic detoxification factors, such as gluta-
thione transferase or P-glycoprotein homologues. Thus, a con-
stant exposure to a certain drug level might become inefficient
with time, leading to regrowth of parasites after an initial reduc-
tion in parasite weight. Clearly, more work needs to be done to
clarify these aspects of the experimental system for murine AE.
In summary, three di-N-aryl-diguanidino compounds with a
thiophene core (DB869, DB871, andDB1127) displayed potential
toxicity against E. multilocularismetacestodes in vitro, while com-
pounds with a furan core lacking the sulfur substitution did not
have any effect. The superior in vitro activity of DB1127 at lower
concentrations could be attributed to the methyl groups of the
benzene rings flanking the thiophene group. DB869, DB871, and
DB1127 showed similar and high cytotoxicity for RH cells, while
toxicity for HFF and Vero cells was lower. Although it is more
cytotoxic than the others, DB1127 did not exhibit adverse effects
in mice upon intraperitoneal or oral application. Parenteral ad-
ministration of DB1127 resulted in significant reduction of para-
site burden in experimentally infectedmice, while oral application
did not. Thus, thiophene-diguanidino derivatives, perhaps prod-
rugs, which retain the characteristics of DB1127 but present an
improved bioavailability when administered orally, hold signifi-
cant potential as treatment options against AE.
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